Skip to main content
Premium Trial:

Request an Annual Quote

US Court Hands Stratagene Victory in Patent Dispute Launched by Invitrogen

For an updated version of this story, click here.

 

SAN FRANCISCO, Feb. 7 - Stratagene has declared legal victory in a patent dispute sparked by Invitrogen.

 

In a final judgment handed down on Jan. 31, the US District Court for the Western District of Texas said that Stratagene did not infringe on Invitrogen patents related to its competent cell products.

 

According to Stratagene, the dispute began when Invitrogen sued the La Jolla, Calif.-based company for allegedly infringing one of its patents, No. 4,981,797. Then, in August last year, Invitrogen voluntarily withdrew its allegations, made against Stratagene's electrocompetent cell and certain chemically competent cell products, Stratagene said.

 

Invitrogen's position further eroded that month when the District Court narrowed its interpretation of the '797 patent, Stratagene said. Following the court's recent decision, Invitrogen withdrew its remaining patent-infringement allegations.

 

Invitrogen did not return phone calls seeking comment.

 

Competent cells, at the heart of the dispute, contain cell walls that have been manipulated to let them absorb various DNA in order to facilitate cloning projects. Stratagene creates various types of competent cell strains.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.